CRISPR-Cas genome engineering company Caribou Biosciences announced that the US Patent and Trademark Office (USPTO) granted Vilnius University a CRISPR-Cas9 genome editing patent.
“Caribou has rights to this intellectual property in multiple fields of use, including exclusive access in the research tools field,” said Caribou.
“Caribou gained these rights as part of its worldwide cross-license agreement with DuPont Company, to which Vilnius University exclusively licensed this intellectual property.”
The Vilnius patent covers methods of modifying DNA using a recombinant CRISPR-Cas9 complex assembled in vitro and is complementary to the exclusive license that Caribou already has from the University of California and the University of Vienna to the foundational CRISPR-Cas9 intellectual property.
“We are delighted to see this important patent grant to Vilnius University,” said Caribou CEO Dr. Rachel Haurwitz.
“These rights are an important addition to the extensive and leading IP portfolio Caribou is building, and will help to facilitate our future technology advancements and product development in gene editing.”